Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Hypotension - Overview
Hypotension - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Hypotension - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hypotension - Companies Involved in Therapeutics Development
Cerecor Inc
Handa Pharmaceuticals LLC
La Jolla Pharmaceutical Company
Theravance Biopharma Inc
TrioxBio Inc
Hypotension - Drug Profiles
ampreloxetine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
angiotensin II acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dopamine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HND-024 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MTR-105 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MTR-107 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
phenylephrine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rislenemdaz - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Hypotension - Dormant Projects
Hypotension - Product Development Milestones
Featured News & Press Releases
Jul 22, 2019: Theravance Biopharma reports new data from phase 2 study of ampreloxetine (TD-9855) in oral presentation at 32nd European Neurology Congress
Jun 28, 2019: La Jolla Pharmaceutical Company receives positive CHMP opinion for GIAPREZA (angiotensin II) for the treatment of refractory Hypotension in adults with septic or other distributive shock
Jun 18, 2019: Theravance Biopharma reports new data from phase 2 study of Ampreloxetine (TD-9855) in presentation at 2019 Intertiol Association of Parkinsonism and Related Disorders (IAPRD) World Congress
Jun 11, 2019: BrePco Biopharma announce the presentation of selected results of late-stage clinical trial in extremely premature neotes
Mar 25, 2019: Theravance Biopharma announces Ampreloxetine (TD-9855) phase 2 study results selected for oral presentation at 32nd European Neurology Congress
Jan 29, 2019: Theravance doses first patient in Phase III trial of ampreloxetine
Aug 01, 2018: Theravance Biopharma reports positive top-line four-week data from phase 2 trial of TD-9855 for the treatment of symptomatic neurogenic orthostatic hypotension
May 29, 2018: TrioxBio Announces Fast Track Desigtion Granted by U.S. FDA to Raviten for the Treatment of Intradialytic Hypotension
Sep 25, 2017: La Jolla Pharmaceutical Company Announces Intent to Submit Marketing Authorization Application for LJPC-501 in the Third Quarter of 2018
Sep 20, 2017: Prespecified Alysis of ATHOS-3 Indicates Survival Benefit in LJPC-501-Treated Patients with Relatively Low Angiotensin II State
Aug 28, 2017: La Jolla Pharmaceutical Company Announces U.S. FDA Acceptance of New Drug Application for LJPC-501
Aug 08, 2017: La Jolla Pharmaceutical Company Announces Launch of Expanded Access Program for LJPC-501
May 21, 2017: Results of ATHOS-3 Phase 3 Study of LJPC-501 Published in The New England Jourl of Medicine
Feb 27, 2017: La Jolla Pharmaceutical Company Announces Positive Top-Line Results from ATHOS-3 Phase 3 Study of LJPC-501
Nov 30, 2015: La Jolla Pharmaceutical Company Announces Notice of Allowance for U.S. Patent Covering LJPC-501
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Hypotension, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products by Targets, H2 2019
Number of Products by Stage and Targets, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019


List of Tables


Number of Products under Development for Hypotension, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Hypotension - Pipeline by Cerecor Inc, H2 2019
Hypotension - Pipeline by Handa Pharmaceuticals LLC, H2 2019
Hypotension - Pipeline by La Jolla Pharmaceutical Company, H2 2019
Hypotension - Pipeline by Theravance Biopharma Inc, H2 2019
Hypotension - Pipeline by TrioxBio Inc, H2 2019
Hypotension - Dormant Projects, H2 2019